Where does Relay Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$272.71M+1.4%	-$276.48M+7.1%	-$297.59M+4.5%	-$311.55M+6.6%	-$333.39M+1.3%
Depreciation and amortization	$2.85M-19.8%	$3.56M-17.1%	$4.29M-12.6%	$4.91M-6.9%	$5.28M-3.4%
Stock-based compensation	$53.63M-14.1%	$62.42M-6.8%	$66.99M-9.4%	$73.94M-14.3%	$86.28M-8.4%
Change in accounts payable	-$4.33M+62.2%	-$11.44M-280%	$6.36M+148%	$2.56M-61.9%	$6.72M-34.6%
Change in other liabilities	——	——	——	-$159K-895%	$20K-97.5%
Change in deferred revenue	——	——	——	——	-$1.92M-125%
Change in prepaid expenses	-$12.91M-701%	-$1.61M-173%	$2.21M-72.1%	$7.91M-11.7%	$8.96M+62.8%
Net cash from operating activities	-$213.36M+9.4%	-$235.46M+5.2%	-$248.46M+5.0%	-$261.42M+3.9%	-$271.99M-9.2%
Capital expenditures	——	$411K+0.2%	$410K-35.6%	$637K+2.4%	$622K-69.2%
Purchases of investments	$151.9M+23.5%	$122.97M-25.0%	$164.05M-55.8%	$371.11M-23.0%	$481.82M-25.9%
Proceeds from maturities/sales of investments	$335.16M+6.0%	$316.18M-9.9%	$350.79M-10.6%	$392.19M-17.1%	$473.29M-22.6%
Net cash from investing activities	$183.24M-5.0%	$192.8M—	——	——	——
Net cash from financing activities	——	——	——	——	——
Net increase (decrease) in cash	——	——	——	——	-$59.91M-199%
Accretion (Amortization) of Discounts and Premiums, Investments	$4.13M-16.5%	$4.95M-21.1%	$6.27M-24.9%	$8.35M-18.5%	$10.25M-16.8%
Depreciation	$2.85M-19.8%	$3.56M-17.1%	$4.29M-12.6%	$4.91M-6.9%	$5.28M-3.4%
Gain (Loss) on Sale of Investments	——	——	——	——	——
Deferred revenue	——	——	——	——	-$1.92M-125%
Increase Decrease In Operating Lease Assets And Liabilities Net	——	——	——	$4.72M+502%	-$1.18M+5.4%
Increase (Decrease) in Prepaid Expense	-$12.91M-701%	-$1.61M-173%	$2.21M-72.1%	$7.91M-11.7%	$8.96M+62.8%
Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options	——	——	——	——	——
Proceeds From Issuance Of Common Stock Via At The Market Offerings Net	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	$6.91M—	——	——	——
Periodic Change In Additions Of Property And Equipment Within Current Liabilities	——	——	——	——	——
Periodic Change In Costs To Obtain License Agreement Within Current Liabilities	——	——	——	——	-$627K-125%
Free cash flow	——	-$235.87M+5.2%	-$248.87M+5.0%	-$262.06M+3.9%	-$272.62M-8.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Relay Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.